Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
162 Results for "
FKBP
" in MedChemExpress (MCE) Product Catalog:
Products (162)
162 Results for "FKBP" in MCE Product Catalog:
1369
1369 Publications Verification
Synonyms: Sirolimus; AY-22989; NSC 226080
118
118 Cited Publications
Synonyms: RAD001; SDZ-RAD
Research Areas:
Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective, orally active, blood-brain barrier-permeable mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
102
102 Cited Publications
Synonyms: FK506; Fujimycin; FR900506
102
102 Cited Publications
Synonyms: FK506 monohydrate; Fujimycin monohydrate; FR900506 monohydrate
57
Rimiducid (AP1903) is a dimerizer agent that acts by cross-linking the FKBP domains. Rimiducid (AP1903) dimerizes the Caspase 9 suicide switch and rapidly induces apoptosis.
54
54 Cited Publications
Synonyms: B/B Homodimerizer
Target:
Research Areas:
AP20187 (B/B Homodimerizer) is a cell-permeable ligand used to dimerize FK506-binding protein (FKBP) fusion proteins and initiate biological signaling cascades and gene expression or disrupt protein-protein interactions.
14
14 Cited Publications
RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin (HY-10219) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR. RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy. Anticancer activity .
11
Shield-1 (Shld1) is a specific, cell-permeant and high-affinity ligand of FK506-binding protein-12 (FKBP), and reverses the instability by binding to mutated FKBP (mtFKBP), allowing conditional expression of mtFKBP-fused proteins. Shield-1 can stabilize proteins tagged with a mutated FKBP12-derived destabilization domain (DD) .
11
Target:
Research Areas:
FKBP12 PROTAC dTAG-13 (dTAG-13) is a FKBP12 F36V PROTAC degrader and a PXR partial agonist. FKBP12 PROTAC dTAG-13 induces ubiquitination and proteasomal degradation of proteins tagged with FKBP12 F36V, without degrading wild-type FKBP12 or un-fused PXR. It weakly promotes the recruitment of SRC-1, strongly inhibits the interaction between NCoR and PXR, and upregulates the expression of CYP3A4 and other drug metabolism-related genes. FKBP12 PROTAC dTAG-13 is applicable to research related to breast cancer and leukemia [1] .
6
6
6 Cited Publications
dTAGV-1 hydrochloride is a potent and selective degrader of FKBP12 F36V-tagged proteins PROTAC degrader. dTAGV-1 hydrochloride can induce degradation of FKBP12 F36V-Nluc in vivo .
6
6 Cited Publications
Cat. No.: HY-145514D
CAS No.: 2451573-86-5
dTAGV-1 is a potent and selective degrader of FKBP12 F36V-tagged proteins PROTAC degrader. dTAGV-1 can induce degradation of FKBP12 F36V-Nluc in vivo.
3
Target:
Research Areas:
FKBP12 PROTAC dTAG-7 (dTAG-7) is a heterobifunctional PROTAC degrader. FKBP12 PROTAC dTAG-7 targets FKBP12 F36V and BET BRD4. FKBP12 PROTAC dTAG-7 enables rapid and selective degradation of target proteins, and is suitable for cellular and in vivo studies to analyze protein functions and validate targets .
2
2 Cited Publications
Cat. No.: HY-P80837
Synonyms: MTOR; FRAP; FRAP1; FRAP2; RAFT1; RAPT1; Serine/threonine-protein kinase mTOR; FK506-binding protein 12-rapamycin complex-associated protein 1; FKBP12-rapamycin complex-associated protein; Mammalian target of rapamycin; mTOR; Mechanistic tar
1
1 Cited Publications
Research Areas:
SLF is a synthetic ligand for FK506-binding protein (FKBP) with an affinity of 3.1 μM for FKBP51 and an IC50 of 2.6 μM for FKBP12. SLF can be used in the synthesis of PROTAC .
1
1 Cited Publications
Synonyms: PROTAC FKBP12-binding moiety 2
Research Areas:
AP1867-2-(carboxymethoxy), the AP1867 (a synthetic FKBP12 F36V-directed ligand) based moiety, binds to CRBN ligand via a linker to form dTAG molecules .
1
1 Cited Publications
dTAG-47 is a FKBP12(F36V) PROTAC degrader. dTAG-47 efficiently degrades FKBP12(F36V)-MELK(sg3R) in MELK ?/? MDA-MB-468-FKBP12(F36V)-MELK(sg3R) cells. dTAG-47 can be used for the research of basal-like breast cancers (BBC) .
1
1 Cited Publications
Target:
Research Areas:
SAFit1 is a FK506 binding protein 51 (FKBP51)-specific inhibitor with a Ki of 4±0.3 nM .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
